Weiss, B. D., Wolters, P. L., Plotkin, S. R., Widemann, B. C., Tonsgard, J. H., Blakeley, J., . . . Fisher, M. J. (2021). NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol.
Chicago Style citaatWeiss, Brian D., et al. "NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas." J Clin Oncol 2021.
MLA citatieWeiss, Brian D., et al. "NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas." J Clin Oncol 2021.